50 to $750 -- was portfolio manager for the hedge fund MSMB
Capital Management LP from October 2009 to March 2014, and also served as portfolio manager of another hedge fund he founded and controlled, MSMB
US biopharmaceutical firm Amag Pharmaceuticals (NASDAQ:AMAG) said its board had snubbed the buyout bid by private equity firm MSMB
Capital Management, as it was not superior to its agreed tie-up with Allos Therapeutics (NASDAQ:ALTH).
believes that its offer is superior and more beneficial to Amag's stockholders than the proposed no-premium merger between Amag and Allos Therapeutics.
level is affected by a genetic change linked to prostate cancer.
reported that it was making its offer public after privately communicating with SeraCare.
3] Human genes: KLK3, kallikrein-related peptidase 3; TERT, telomerase reverse transcriptase; FGFR2, fibroblast growth factor receptor 2; MSMB
, microsemino- protein, beta-; TBX3, T-box 3; HNF1B, HNF1 homeobox B.
Men found to have low levels of MSMB
could then be closely monitored, with the aim of detecting the disease, if it does indeed develop, as early as possible.
In addition to security fraud, the 34-year-old is accused of wire fraud, conspiracy, and mismanaging money at his investment funds Elea Capital, MSMB
Healthcare, as well as while CEO of Retrophin (RTRX), the pharmaceutical company he founded in 2011.
Earlier this month, MSMB
, a long-term investor in Amag, has proposed to buy the rest of the company not yet owned at USD18.
He was accused of using MSMB
Capital Management, the hedge fund he created in 2009, and Retrophin "like a personal piggy bank," U.
CAPITAL ANNOUNCES BUYOUT BID FOR AMAG PHARMACEUTICALS